|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This difference was confirmed in GESPIC with 73% of AS patients being HLA-C*07 negative compared to 50% of the controls (p < 0.0001); 59% of the nr-axSpA patients were HLA-C*07 negative.
|
30809016 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-B*40:02 is one of a few major histocompatibility complex class I (MHC-I) molecules associated with ankylosing spondylitis (AS) independently of HLA-B*27.
|
31530632 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other MHC-I-opathies include ankylosing spondylitis and HLA-B*27-associated spondyloarthropathies and HLA-C*0602-associated skin psoriasis.
|
28898393 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Four inflammatory diseases are strongly associated with Major Histocompatibility Complex class I (MHC-I) molecules: birdshot chorioretinopathy (HLA-A<sup>*</sup>29:02), ankylosing spondylitis (HLA-B<sup>*</sup>27), Behçet's disease (HLA-B<sup>*</sup>51), and psoriasis (HLA-C<sup>*</sup>06:02).
|
30425713 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human Leukocyte Antigen C*12:02:02 and Killer Immunoglobulin-Like Receptor 2DL5 are Distinctly Associated with Ankylosing Spondylitis in the Taiwanese.
|
28812990 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA-B27 is a class I major histocompatibility (MHC-I) allele that confers susceptibility to the rheumatic disease ankylosing spondylitis (AS) by an unknown mechanism.
|
28188227 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ankylosing spondylitis (AS) is an inflammatory disease strongly associated with the Major Histocompatibility Complex class I (MHC-I) allotype HLA-B*27.
|
28063628 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
KIR3DL1 interaction with HLA-B27 is altered by ankylosing spondylitis associated ERAP1 and enhanced by MHC class I cross-linking.
|
26321090 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the role of non-MHC pathogenic pathways in susceptibility to AS and warrants more comprehensive studies focusing on these non-MHC pathways for developing novel therapeutic strategies.
|
26590821 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review will focus on the four major MHC-I-associated inflammatory disorders: ankylosing spondylitis, birdshot chorioretinopathy, Behçet's disease and psoriasis.
|
27522479 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population.
|
26613595 |
2015 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ERAP1 structure, function and pathogenetic role in ankylosing spondylitis and other MHC-associated diseases.
|
23916068 |
2014 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I region, ERAP1 and IL23R and the MHC class I-ERAP1 interaction), as well as two loci shared with inflammatory bowel disease (IL23R and IL10) implicate shared pathogenic pathways in the spondyloarthritides and Behçet's disease.
|
23291587 |
2013 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increasing number of non-MHC genetic associations have been reported, which provided amongst other things the first evidence of the involvement of the IL-23 pathway in AS.
|
23083754 |
2012 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, individuals with AS showed an increased frequency of HLA-Cw*08 (p = 0.001, p (c) = 0.008) compared with that in controls.
|
20652381 |
2010 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, the simultaneous presence of KIR2DS5 gene and HLA-C C1 allotype exhibited an even stronger protective effect on ankylosing spondylitis (p=0.0003, OR=0.35, CI=0.19-0.65), whereas a lack of KIR2DS5 and the presence of the HLA-C C2 allotype was associated with ankylosing spondylitis (p=0.0017, OR=1.92, CI=1.28-2.89), whereas a lack of KIR2DS5 and presence of C1 allotype was associated with rheumatoid arthritis (p=0.005, OR=1.47, CI=1.13-1.92).
|
20865034 |
2010 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
200 random controls, 120 patients with AS and 175 HLA-B27 positive controls were genotyped for six single nucleotide polymorphisms (SNPs) spanning the HLA region between HLA-E and HLA-C loci previously shown to harbour an additional susceptibility locus for AS.
|
19912639 |
2009 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The genotype 2DS1+/HLA-C lys(80)+ was more common in subjects with AS.
|
18297378 |
2008 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To define the genetic basis of susceptibility to ankylosing spondylitis (AS), especially non-major histocompatibility complex (MHC) genes.
|
15248224 |
2004 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results strongly support the presence of non-MHC genetic-susceptibility factors in AS and point to their likely locations.
|
11231900 |
2001 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MICA-A4 was found to be in association with B*2705,02,03 and 08; MICA-A5 with B*2704 and B*2707 and MICA-A.5.1 with B*2706; (c) no significant differences of MICA alleles were found between AS and controls carrying the B27-associated alleles, and therefore no evidence is provided for an additional role of MICA gene in AS susceptibility; (d) there are a striking correlations between the structure of B27 extended haplotypes (from MICA region to HLA-C) and the ethnic distribution of these subtypes.
|
10717805 |
2000 |